{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:50:49Z","timestamp":1782215449809,"version":"3.54.5"},"reference-count":31,"publisher":"Termedia Sp. z.o.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Pathol"],"abstract":"<jats:p>The\u00a0BRAF mutation has been observed in 32\u201373% of\u00a0papillary thyroid carcinomas. Despite the\u00a0superiority of\u00a0genetic tests for detecting BRAF mutations, they have inherent disadvantages. The\u00a0objective of\u00a0this study was to analyze the\u00a0specificity and sensitivity of\u00a0BRAF immunohistochemistry (IHC) that has been used in recent years and may serve as an alternative to genetic testing, in papillary thyroid carcinoma.&lt;br \/&gt;\nA\u00a0total of\u00a0103 cases of\u00a0papillary thyroid carcinoma were analyzed for BRAF V600E mutation by real-time polymerase chain reaction (PCR) and IHC.&lt;br \/&gt;\nThe\u00a0results demonstrated that the\u00a0BRAF V600E mutation was identified in  55 (53.3%) of\u00a0103 cases by real-time PCR, while BRAF IHC positivity was observed in 65 (63.1%) of\u00a0103 cases. The\u00a0study found that the\u00a0specificity of\u00a0BRAF IHC was 79.2%, while the\u00a0sensitivity was 100%. The\u00a0real-time PCR analysis identified  10 cases that were positive for BRAF IHC and exhibited wild-type BRAF. &lt;br \/&gt;\nBRAF IHC can be utilized as a\u00a0screening test and as a\u00a0partial alternative to genetic tests. This is due to its low cost, straightforward routine application, moderate to high specificity, and high sensitivity.<\/jats:p>","DOI":"10.5114\/pjp.2025.158888","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:22:08Z","timestamp":1769599328000},"page":"292-298","source":"Crossref","is-referenced-by-count":0,"title":["Utility of\u00a0BRAF immunohistochemistry for the\u00a0detection of\u00a0BRAF mutations in papillary thyroid carcinoma. Analysis of\u00a0detailed histological subtypes"],"prefix":"10.5114","volume":"76","author":[{"given":"Evren","family":"Uzun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suna","family":"Erkilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref-1687471","doi-asserted-by":"crossref","unstructured":"Davies L, Welch HG. Increasing incidence of\u00a0thyroid cancer in the\u00a0United States, 1973\u20132002.\u00a0Jama 2006;\u00a0295: 2164-2167.","DOI":"10.1001\/jama.295.18.2164"},{"key":"ref-1687472","doi-asserted-by":"crossref","unstructured":"Hunt JL, Tometsko M, LiVolsi VA, Swalsky P,\u00a0Finkelstein SD, Barnes EL. Molecular evidence of\u00a0anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of\u00a0the\u00a0thyroid.\u00a0Am J Surg Pathol 2003;\u00a027: 1559-1564.","DOI":"10.1097\/00000478-200312000-00009"},{"key":"ref-1687473","doi-asserted-by":"crossref","unstructured":"Kim TY, Kim WB, Rhee YS, Song J,\u00a0Kim M,\u00a0Gong G, et al. The\u00a0BRAF mutation is useful for prediction of\u00a0clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.\u00a0Clin Endocrinol 2006; 65: 364-368.","DOI":"10.1111\/j.1365-2265.2006.02605.x"},{"key":"ref-1687474","doi-asserted-by":"crossref","unstructured":"Yip L, Nikiforova MN, Carty SE, Yim JH,\u00a0Stang MT,\u00a0Tublin MJ, et al. Optimizing surgical treatment of\u00a0papillary thyroid carcinoma associated with BRAF mutation.\u00a0Surgery 2009;\u00a0146: 1215-1223.","DOI":"10.1016\/j.surg.2009.09.011"},{"key":"ref-1687475","doi-asserted-by":"crossref","unstructured":"Ihle MA, Fassunke J, K\u00f6nig K, Gr\u00fcnewald I,\u00a0Schlaak M, Kreuzberg N,\u00a0et al. Comparison of\u00a0high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the\u00a0detection of\u00a0p. V600E and non-p. V600E BRAF mutations.\u00a0BMC Cancer 2014;\u00a014: 1-13.","DOI":"10.1186\/1471-2407-14-13"},{"key":"ref-1687476","doi-asserted-by":"crossref","unstructured":"Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, et al. A\u00a0mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.\u00a0Target Oncol 2015; 10: 99-109.","DOI":"10.1007\/s11523-014-0319-8"},{"key":"ref-1687477","doi-asserted-by":"crossref","unstructured":"Capper D, Preusser M, Habel A, Sahm F,\u00a0Ackermann U,\u00a0Schindler G, et al. Assessment of\u00a0BRAF V600E mutation status by immunohistochemistry with a\u00a0mutation-specific monoclonal antibody.\u00a0Acta Neuropathol 2011;\u00a0122: 11-19.","DOI":"10.1007\/s00401-011-0841-z"},{"key":"ref-1687478","doi-asserted-by":"crossref","unstructured":"Dvorak K, Aggeler B, Palting J, McKelvie P,\u00a0Ruszkiewicz A, Waring P. Immunohistochemistry with the\u00a0anti-BRAF V600E (VE1) antibody: impact of\u00a0pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.\u00a0Pathology 2014; 46: 509-517.","DOI":"10.1097\/PAT.0000000000000119"},{"key":"ref-1687479","doi-asserted-by":"crossref","unstructured":"Ghossein RA, Katabi N, Fagin JA. Immunohistochemical detection of\u00a0mutated BRAF V600E supports the\u00a0clonal origin of\u00a0BRAF-induced thyroid cancers along the\u00a0spectrum of\u00a0disease progression.\u00a0J Clin Endocrinol Metabol 2013;\u00a098: E1414-E1421.","DOI":"10.1210\/jc.2013-1408"},{"key":"ref-1687480","doi-asserted-by":"crossref","unstructured":"Koperek O, Kornauth C, Capper D, Berghoff AS,\u00a0Asari R,\u00a0Niederle B, et al. Immunohistochemical detection of\u00a0the\u00a0BRAF V600E-mutated protein in papillary thyroid carcinoma. Am  J Surg Pathol 2012; 36: 844-850.","DOI":"10.1097\/PAS.0b013e318246b527"},{"key":"ref-1687481","doi-asserted-by":"crossref","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.\u00a0Nat Rev Cancer 2014; 14: 455-467.","DOI":"10.1038\/nrc3760"},{"key":"ref-1687482","doi-asserted-by":"crossref","unstructured":"Zambon A, Niculescu-Duvaz D, Niculescu-Duvaz I, Marais R, Springer CJ. BRAF as a\u00a0therapeutic target: a\u00a0patent review (2006\u20132012).\u00a0Expert Opin Ther Pat 2013;\u00a023: 155-164.","DOI":"10.1517\/13543776.2013.741593"},{"key":"ref-1687483","doi-asserted-by":"crossref","unstructured":"Sancisi V, Nicoli D, Ragazzi M, Piana S,\u00a0Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.\u00a0J Clin Endocrinol Metab 2012;\u00a097: E1745-E1749.","DOI":"10.1210\/jc.2012-1526"},{"key":"ref-1687484","doi-asserted-by":"crossref","unstructured":"Namba H, Nakashima M, Hayashi T, Hayashida N,\u00a0Maeda S, Rogounovitch TI, et al. Clinical implication of\u00a0hot spot BRAF mutation, V599E, in papillary thyroid cancers.\u00a0J Clin Endocrinol Metab 2003;\u00a088: 4393-4397.","DOI":"10.1210\/jc.2003-030305"},{"key":"ref-1687485","doi-asserted-by":"crossref","unstructured":"Hiltzik D, Carlson DL, Tuttle RM, Chuai S,\u00a0Ishill N,\u00a0Shaha A, et al. Poorly differentiated thyroid carcinomas defined on the\u00a0basis of\u00a0mitosis and necrosis: a\u00a0clinicopathologic study of\u00a058 patients.\u00a0Cancer 2006;\u00a0106: 1286-1295.","DOI":"10.1002\/cncr.21739"},{"key":"ref-1687486","doi-asserted-by":"crossref","unstructured":"Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets.\u00a0Mod Pathol 2008; 21: S37-S43.","DOI":"10.1038\/modpathol.2008.10"},{"key":"ref-1687487","doi-asserted-by":"crossref","unstructured":"Trovisco V, Soares P, Preto A, de Castro IV,\u00a0Lima J,\u00a0Castro P, et al. Type and prevalence of\u00a0BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients\u2019 age but not with tumour aggressiveness.\u00a0Virchows Arch 2005;\u00a0446: 589-595.","DOI":"10.1007\/s00428-005-1236-0"},{"key":"ref-1687488","doi-asserted-by":"crossref","unstructured":"Routhier CA, Mochel MC, Lynch K, Dias-Santagata D,\u00a0Louis DN,\u00a0Hoang MP. Comparison of\u00a02 monoclonal antibodies for immunohistochemical detection of\u00a0BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 2013; 44: 2563- 2570.","DOI":"10.1016\/j.humpath.2013.06.018"},{"key":"ref-1687489","doi-asserted-by":"crossref","unstructured":"Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S,\u00a0Modica DDC,\u00a0Turrini L, et al. Immunohistochemistry for BRAF(V600E) antibody VE1 per- formed in core needle biopsy samples identifies mutated papillary thyroid cancers. Horm Metab Res 2014; 46: 370-374.","DOI":"10.1055\/s-0034-1368700"},{"key":"ref-1687490","doi-asserted-by":"crossref","unstructured":"Martinuzzi C, Pastorino L, Andreotti V, Garuti A,\u00a0Minuto M, Fiocca R, et al. A\u00a0combination of\u00a0immunohistochemistry and molecular approaches improves highly sensitive detection of\u00a0BRAF mutations in papillary thyroid cancer.\u00a0Endocrine 2016; 53: 672-680.","DOI":"10.1007\/s12020-015-0720-9"},{"key":"ref-1687491","doi-asserted-by":"crossref","unstructured":"Parker KG, White MG, Cipriani NA. Comparison of\u00a0molecular methods and BRAF immunohistochemistry (VE1 clone) for the\u00a0detection of\u00a0BRAF V600E mutation in papillary thyroid carcinoma: a\u00a0meta-analysis.\u00a0Head Neck Pathol 2020;\u00a014: 1067-1079.","DOI":"10.1007\/s12105-020-01166-8"},{"key":"ref-1687492","doi-asserted-by":"crossref","unstructured":"Bullock M, O\u2019Neill C, Chou A, Clarkson A,\u00a0Dodds T,\u00a0Toon C, et al. Utilization of\u00a0a\u00a0MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012; 19: 779-784.","DOI":"10.1530\/ERC-12-0239"},{"key":"ref-1687493","doi-asserted-by":"crossref","unstructured":"Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, et al. Diagnostic value of\u00a0immunohistochemistry for the\u00a0detection of\u00a0the\u00a0BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid 2014; 24: 858-866.","DOI":"10.1089\/thy.2013.0302"},{"key":"ref-1687494","doi-asserted-by":"crossref","unstructured":"Kim YH, Choi SE, Yoon SO, et al. (2014) A\u00a0testing algorithm for detection of\u00a0the\u00a0B-type Raf kinase V600E mutation in papillary thyroid carcinoma. Hum Pathol 45(7):1483-1488. doi:10.1016\/j. humpath.2014.02.025.","DOI":"10.1016\/j.humpath.2014.02.025"},{"key":"ref-1687495","unstructured":"Moskaluk CA, Kern SE. Microdissection and polymerase chain reaction amplification of\u00a0genomic DNA from histological tissue sections. Am J Pathol 1997; 150:1547-1552."},{"key":"ref-1687496","doi-asserted-by":"crossref","unstructured":"Jung YY, Yoo JH, Park ES, Kyung Kim M,\u00a0Lee TJ,\u00a0Cho BY, et al. Clinicopathologic correlations of\u00a0the\u00a0BRAF(V600E) mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Pathol Res Pract 2015; 211: 162-170.","DOI":"10.1016\/j.prp.2014.10.005"},{"key":"ref-1687497","doi-asserted-by":"crossref","unstructured":"Rossi ED, Martini M, Capodimonti S, Cenci T,\u00a0Straccia P,\u00a0Angrisani B, et al. Analysis of\u00a0immunocytochemical and molecular BRAF expression in thyroid carcinomas: a\u00a0cytohistologic institutional experience. Cancer Cytopathol 2014; 122: 527-535.","DOI":"10.1002\/cncy.21416"},{"key":"ref-1687498","doi-asserted-by":"crossref","unstructured":"Zagzag J, Pollack A, Dultz L, Dhar S,\u00a0Ogilvie JB,\u00a0Heller KS,  et al. Clinical utility of\u00a0immunohistochemistry for the\u00a0detection of\u00a0the\u00a0BRAF v600e mutation in papillary thyroid carcinoma. Surgery 2013; 154: 1199-1204.","DOI":"10.1016\/j.surg.2013.06.020"},{"key":"ref-1687499","doi-asserted-by":"crossref","unstructured":"Na JI, Kim JH, Kim HJ, Kim HK,\u00a0Moon KS,\u00a0Lee JS, et al. VE1 immunohistochemical detection of\u00a0the\u00a0BRAF V600E mutation in thyroid carcinoma: a\u00a0review of\u00a0its usefulness and limitations.\u00a0Virchows Archiv 2015; 467: 155-168.","DOI":"10.1007\/s00428-015-1773-0"},{"key":"ref-1687500","doi-asserted-by":"crossref","unstructured":"Kim HS, Kim JO, Lee DH, Lee HC,\u00a0Kim HJ,\u00a0Kim JH, et al. Factors influencing the\u00a0detection of\u00a0the\u00a0BRAF T1799A mutation in papillary thyroid carcinoma. Oncol Rep 2011; 25: 1639-1644.","DOI":"10.3892\/or.2011.1225"},{"key":"ref-1687501","doi-asserted-by":"crossref","unstructured":"Abd Elmageed ZY, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F,\u00a0Moroz K, et al. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of\u00a0papillary thyroid cancer.\u00a0Surgery 2017; 161: 1122-1128.","DOI":"10.1016\/j.surg.2016.06.081"}],"container-title":["Polish Journal of Pathology"],"original-title":[],"link":[{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-215552-136491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-215552-136491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:12:48Z","timestamp":1782213168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polishjournalofpathology.com\/Utility-of-BRAF-immunohistochemistry-for-the-detection-of-BRAF-mutations-in-papillary,215552,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"alternative-id":["215552"],"URL":"https:\/\/doi.org\/10.5114\/pjp.2025.158888","relation":{},"ISSN":["1233-9687","2084-9869"],"issn-type":[{"value":"1233-9687","type":"print"},{"value":"2084-9869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}